Key regions: United Kingdom, Brazil, Europe, France, Canada
The use of Anti-Fibrinolytic Drugs has been on the rise in Zambia in recent years.
Customer preferences: Zambian customers have shown a growing demand for Anti-Fibrinolytic Drugs due to an increase in the number of surgical procedures being performed in the country. This trend has been observed in both private and public hospitals. Additionally, there has been a growing awareness among healthcare professionals of the benefits of using Anti-Fibrinolytic Drugs during surgeries, leading to an increase in their usage.
Trends in the market: The Anti-Fibrinolytic Drugs market in Zambia has been growing steadily over the past few years, driven by the increasing number of surgical procedures being performed in the country. The market is expected to continue growing in the coming years, as the government continues to invest in healthcare infrastructure and as more people become aware of the benefits of Anti-Fibrinolytic Drugs.
Local special circumstances: Zambia is a developing country with a growing population and a rising middle class. The government has been investing heavily in healthcare infrastructure in recent years, with a focus on improving access to healthcare services in rural areas. This has led to an increase in the number of hospitals and healthcare facilities in the country, which in turn has driven the demand for Anti-Fibrinolytic Drugs.
Underlying macroeconomic factors: Zambia's economy has been growing steadily in recent years, driven by the country's mining and agriculture sectors. This has led to an increase in disposable income among the population, which has in turn driven demand for healthcare services. Additionally, the government has been investing heavily in infrastructure projects, including healthcare facilities, which has led to an increase in the availability of healthcare services in the country. These underlying macroeconomic factors are expected to continue driving the growth of the Anti-Fibrinolytic Drugs market in Zambia in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
